Please use this identifier to cite or link to this item:
|Title:||Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.|
|Abstract:||In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal analysis of quality of life (QoL) in RECOURSE. The aim of the present analysis was to assess proxies of QoL during the RECOURSE treatment period, in terms of adverse events (AEs) likely to affect QoL and Eastern Cooperative Oncology Group performance status (ECOG PS).|
|Appears in Collections:||Hospitales > H. U. 12 de Octubre > Artículos|
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.